Intranasal mupirocin reduces sternal wound infection after open heart surgery in diabetics and nondiabetics

Annals of Thoracic Surgery

Volumn 71, Issue 5, 2001, Pages 1572-1579

  Cimochowski, George E ^a   Harostock, Michael D ^a   Brown, Robert ^a   Bernardi, Mark ^a   Alonzo, Nancy ^a   Coyle, Kathy ^a  

^a Wilkes Barre General Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PSEUDOMONIC ACID;

ADULT; AGED; ARTICLE; BACTERIAL COLONIZATION; COMORBIDITY; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DRUG COST; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OPEN HEART SURGERY; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROPHYLAXIS; TREATMENT OUTCOME; TREATMENT PLANNING; WOUND INFECTION;

ADMINISTRATION, INTRANASAL; AGED; ANTIBIOTIC PROPHYLAXIS; CORONARY ARTERY BYPASS; CORONARY DISEASE; DIABETIC ANGIOPATHIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LENGTH OF STAY; MALE; MIDDLE AGED; MUPIROCIN; NASAL MUCOSA; STERNUM; SURGICAL WOUND INFECTION; TREATMENT OUTCOME;

EID: 0035015238     PISSN: 00034975     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0003-4975(01)02519-X     Document Type: Article

References (25)

1. Zacharias A., Habib R.H. Factors predisposing sternotomy complications deep vs superficial infection. Chest. 110:1996;1173-1178.
2. Vuorisalo S., Haukipuro K., Pokela R., et al. Risk features for surgical-site infections in coronary artery bypass surgery. Infect Control Hosp Epidemiol. 19:1998;240-247.
3. Roy M.C. Surgical-site infections after coronary artery bypass graft surgery discriminating site-specific risk factors to improve prevention efforts. Infect Control Hosp Epidemiol. 19:1998;229-233.
4. L'Ecuyer P.B., Murphy D., Little R., et al. The epidemiology of chest and leg wound infections following cardiothoracic surgery. Clin Infect Dis. 22:1996;424-429.
5. Nagachinta T., Stephens M., Reitz B., et al. Risk factors for surgical wound infection following cardiac surgery. J Infect Dis. 156:1987;967-973.
6. Williams R.E.O., Jevons M.P., Shooter R.A., et al. Nasal staphylococci and sepsis in hospital patients. Br Med J. ii:1959;658-662.
7. Weinstein H.J. The relation between the nasal-staphylococcal-carrier state and the incidence of postoperative complications. N Engl J Med. 260:1959;1303-1308.
8. Kluytmans J.A.J.W., Mouton J.W., Ijzerman E.P.F., et al. Nasal carriage of staphylococcus aureus as a major risk factor for wound infections after cardiac surgery. J Infect Dis. 171:1995;216-219.
9. Kluytmans J. Reduction of surgical site infections in major surgery by elimination of nasal carriage of staphylococcus aureus. J Hosp Infect. 40:1998;S25-S29.
10. Nelson R.M., Dries D.J. The economic implications of infection in cardiac surgery. Ann Thor Surg. 42:1986;240-244.
11. Reagan D.R., Doebbeling B.N., Pfaller M.A., et al. Elimination of coincident staphylococcus aureus nasal and hand carriage with intranasal application of mupirocin calcium ointment. Ann Internl Med. 114:1991;101-106.
12. Ruef C., Fanconi S., Nadal D. Sternal wound infection after heart operations in pediatric patients associated with nasal carriage of staphylococcus aureus. J Cardiovasc Surg. 112:1996;681-686.
13. Kluytmans J.A.J.W., Mouton J.W., VandenBergh M.F.Q., et al. Reduction of surgical-site infections in cardiothoracic surgery by elimination of nasal carriage of staphylococcus aureus. Infect Control Hosp Epidemiol. 17:1996;780-785.
14. Casewell M.W. The nose an underestimated source of staphylococcus aureus causing wound infection. J Hosp Infect. 40:1998;S3-S11.
15. Hudson I.R.B. The efficacy of intranasal mupirocin in the prevention of staphylococcal infections a review of recent experience. J Hosp Infect. 27:1994;81-98.
16. Smith T.L., Pearson M.L., Wilcox K.R., et al. Emergence of vancomycin resistance in staphylococcus aureus. N Engl J Med. 340:1999;493-501.
17. Perl T.M., Golub J.E. New approaches to reduce staphylococcus aureus nosocomial infection rates treating aureus nasal carriage. Ann Pharmacother. 32:(Suppl):1998;7-16.
18. Doebbeling B.N. Elimination of Staphylococcus aureus nasal carriage in health care workers analysis of six clinical trials with calcium mupirocin ointment. Clin Infect Dis. 17:1993;466-474.
19. Zerr K.J., Furnary A.P., Grunkemeier G.L., et al. Glucose control lowers the risk of wound infection in diabetics after open heart operations. Ann Thorac Surg. 63:1998;356-361.
20. American Heart Association. 1996 Stroke and Heart Disease Statistics.
21. Martin J.N., Perdreau-Remington F., Kartalija M., et al. A randomized clinical trial of mupirocin in the eradication of staphylococcus aureus nasal carriage in human immunodeficiency virus disease. J Infect Dis. 180:1999;896-899.
22. Miller M.A., Dascal A., Portnoy J., et al. Development of mupirocin resistance among methicillin-resistant staphylococcus aureus after widespread use of nasal mupirocin ointment. Infect Control Hosp Epidemiol. 17:1996;811-813.
23. Skellem P, Toy G, Lang S. Staphylococcus aureus highly resistant to mupirocin now common in Auckland. N Z Med J 1998;Mar 13;111(1061):82.
24. Boyce J.M. Preventing staphylococcal infections by eradicating nasal carriage of staphylococcus aureus proceeding with caution. Infect Control Hosp Epidemiol. 17:1996;775-779.
25. Harbarth S., Dharan S., Liassine N., et al. Randomized, placebo-controlled, double-blind trial to evaluate the efficacy of mupirocin for eradicating carriage of methicillin-resistant staphylococcus aureus. Antimicrob Agents Chemother. 43:1999;1412-1416.